Pirepemat fumarate

Modify Date: 2024-01-11 19:23:15

Pirepemat fumarate structure	Common Name	Pirepemat fumarate
	CAS Number	2251806-70-7	Molecular Weight	329.30
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₅H₁₇F₂NO₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Pirepemat fumarate

Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2].

Name	Pirepemat fumarate

Description	Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vitro	IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets[2].
In Vivo	IRL752 (3.7-100 µmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2]. Animal Model: Normal rats[2] Dosage: 3.7-100 µmol/kg Administration: S.c., 30 min prior to testing Result: Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.
References	[1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease. [2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419.

Molecular Formula	C₁₅H₁₇F₂NO₅
Molecular Weight	329.30